Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: July-08-15
Credit Expiration Date: July-08-16

Faculty

Wells Messersmith, MD, FACP
Professor of Medicine
Director, GI Medical Oncology Program
Program co-Leader, Developmental Therapeutics
Co-Head, Division of Medical Oncology
University of Colorado Cancer Center
University of Colorado School of Medicine
Aurora, CO

Credit Hours

1.0

Medium

Online Presentation

Program Description

NOTE: This activity was presented as a live visiting faculty grand rounds series beginning on April 16, 2015. Participants who received credit for attending any of the live presentations are not eligible to receive credit for this online release.

Colorectal cancer (CRC) is the second leading cause of cancer death in America, causing roughly 50,000 US deaths annually. Although mortality from colorectal cancer has decreased significantly in the past 2 decades (due largely to earlier diagnosis and improved treatment modalities), there is significant room for improvement with regard to colorectal treatment practice. Clinicians’ efforts are hindered by a lack of guidance stemming from incongruent and frequently changing treatment guidelines and a lack of guidance for treatment monitoring. Likewise, the need for a carefully tailored treatment approach can further complicate care. As new targets and treatments are developed and new research on optimal treatment combinations is conducted, it is likely that standards of care will change considerably.

Program Developer/Facilitator

This activity is jointly provided by Global Education Group and MCM Education

Target Audience

Medical oncologists, radiation oncologists, surgeons, and other oncology clinicians interested and involved in the treatment of patients with CRC.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss recent changes to contemporary versions of colorectal cancer guidelines, and how these changes might impact care.
  2. Describe strategies that can be used to accurately assess treatment response.
  3. Discuss the various treatment combinations that can be used to treat colorectal cancer and the patients who would likely benefit most from each approach.
  4. Summarize recently published findings on investigational agents and treatment strategies for colorectal cancer.

Disclosures

Wells Messersmith, MD, discloses that he has received grant/research support from the following: Genentech/Roche, Pfizer Inc., Bayer

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN: Nothing to disclose
Amanda Glazar, PhD: Nothing to disclose
Andrea Funk: Nothing to disclose
Kathleen Hines (MCM Education editorial director): Nothing to disclose

Credit Statements

ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group and MCM Education. Global Education Group is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT: Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit
In order to obtain credit, participants must review the activity in its entirety and complete the post-test and evaluation.

Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com.

Commercial Support Statements

This activity is supported by an educational grant from Genentech.

Certificate Fee

$0.00

Disclaimer

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and MCM Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS